Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

I-Mab’s Partner MorphoSys Out-Licenses Ex-China Rights for Two Oncology Candidates to HIBio

publication date: Jun 15, 2022

Shanghai I-Mab announced that Human Immunology Bioscience (HIBio) acquired ex-China rights for two assets from Germany's MorphoSys AG. In 2017 and 2018, I-Mab acquired greater China rights to the same candidates, felzartamab (TJ202/MOR202) and TJ210, in two separate deals. Because I-Mab was leading development of the drugs, it also received the right to single-digit royalties from sales outside its China territories, which will be paid by HIBio if the drugs progress to commercialization. More details....

Stock Symbols: (NSDQ: IMAB) (FSE: MOR; NSDQ: MOR)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital